Rosalind Advisors Inc. Makes New $4.65 Million Investment in Verastem, Inc. (NASDAQ:VSTM)

Rosalind Advisors Inc. purchased a new position in Verastem, Inc. (NASDAQ:VSTM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 900,000 shares of the biopharmaceutical company's stock, valued at approximately $4,653,000. Verastem makes up about 2.3% of Rosalind Advisors Inc.'s portfolio, making the stock its 16th biggest holding. Rosalind Advisors Inc. owned approximately 2.02% of Verastem as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of VSTM. Charles Schwab Investment Management Inc. raised its stake in shares of Verastem by 46.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 103,601 shares of the biopharmaceutical company's stock valued at $310,000 after purchasing an additional 32,791 shares in the last quarter. FMR LLC bought a new stake in shares of Verastem in the 3rd quarter valued at approximately $41,000. Stonepine Capital Management LLC acquired a new stake in shares of Verastem during the 3rd quarter valued at approximately $3,918,000. Walleye Capital LLC raised its position in shares of Verastem by 493.7% during the 3rd quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company's stock valued at $646,000 after acquiring an additional 179,725 shares in the last quarter. Finally, Stifel Financial Corp lifted its stake in Verastem by 62.3% during the third quarter. Stifel Financial Corp now owns 30,339 shares of the biopharmaceutical company's stock worth $91,000 after purchasing an additional 11,642 shares during the last quarter. Hedge funds and other institutional investors own 88.37% of the company's stock.

Remove Ads

Verastem Stock Performance

VSTM traded down $0.17 during trading hours on Wednesday, hitting $6.40. The company's stock had a trading volume of 697,064 shares, compared to its average volume of 914,712. The company has a 50-day simple moving average of $6.08 and a 200 day simple moving average of $4.70. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. The firm has a market capitalization of $284.84 million, a PE ratio of -2.01 and a beta of 0.60. Verastem, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $13.52.

Verastem (NASDAQ:VSTM - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.57). As a group, sell-side analysts expect that Verastem, Inc. will post -3.02 EPS for the current year.

Insider Buying and Selling at Verastem

In other news, CEO Dan Paterson sold 8,568 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $5.24, for a total value of $44,896.32. Following the completion of the sale, the chief executive officer now owns 347,581 shares in the company, valued at $1,821,324.44. This represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 9,960 shares of company stock valued at $53,498. 2.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on VSTM shares. Mizuho increased their target price on shares of Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Thursday, December 19th. HC Wainwright increased their price objective on shares of Verastem from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday. Guggenheim lifted their target price on Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Monday. BTIG Research increased their price target on Verastem from $13.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Finally, StockNews.com raised Verastem from a "sell" rating to a "hold" rating in a report on Monday. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $13.88.

Verastem Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.